Search Within

Lisa Bodei

  1. "Neeta Pandit-Taskar"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
Groups
  1. Center for Pancreatic Cancer Research (6)
  2. Molecular Imaging and Therapy Service (6)
  3. Radiology, Department of (6)
  4. Sloan Kettering Institute Postdocs (6)
  5. Department of Medicine (5)
  6. Gastrointestinal Oncology Service (5)

More Groups

People
  1. Neeta Pandit-Taskar (6)
  2. Diane Reidy (5)
  3. Joseph O'Donoghue (5)
  4. Simone Krebs (5)
  5. Wolfgang Weber (5)
  6. Jason Lewis (4)

More People

Years
  1. 2021 (1)
  2. 2020 (1)
  3. 2019 (2)
  4. 2018 (2)
Publications
  1. European Journal of Nuclear Medicine and Molecular Imaging (4)
  2. Clinical Cancer Research (1)
  3. Pancreas (1)
Publishers
  1. Springer (4)
  2. American Association for Cancer Research (1)
  3. Lippincott Williams & Wilkins (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals
    Journal Article

    Kalidindi, T. M.; Lee, S. G.; Jou, K.; Chakraborty, G.; Skafida, M.; Tagawa, S. T.; Bander, N. H.; Schoder, H.; Bodei, L.; Pandit-Taskar, N.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2021)

    Fulltext@MSK | Save
  • Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
    Journal Article

    Krebs, S.; O'Donoghue, J. A.; Biegel, E.; Beattie, B. J.; Reidy, D.; Lyashchenko, S. K.; Lewis, J. S.; Bodei, L.; Weber, W. A.; Pandit-Taskar, N.
    European Journal of Nuclear Medicine and Molecular Imaging (2020)

    Fulltext@MSK | Save
  • Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist (177)Lu-satoreotide tetraxetan
    Journal Article

    Reidy-Lagunes, D.; Pandit-Taskar, N.; O'Donoghue, J. A.; Krebs, S.; Staton, K. D.; Lyashchenko, S. K.; Lewis, J. S.; Raj, N.; Gönen, M.; Lohrmann, C.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Biodistribution and radiation dose estimates for (68)Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors
    Journal Article

    Krebs, S.; Pandit-Taskar, N.; Reidy, D.; Beattie, B. J.; Lyashchenko, S. K.; Lewis, J. S.; Bodei, L.; Weber, W. A.; O'Donoghue, J. A.
    European Journal of Nuclear Medicine and Molecular Imaging (2019)

    Fulltext@MSK | Save
  • Comparison of (68)Ga-DOTA-JR11 PET/CT with (dosimetric) (177)Lu-DOTA-JR11 SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
    Meeting Abstract

    Krebs, S.; O'Donoghue, J.; Biegel, E.; Beattie, B. J.; Reidy, D.; Bodei, L.; Weber, W. A.; Pandit-Taskar, N.
    European Journal of Nuclear Medicine and Molecular Imaging (2018)

    Fulltext@MSK | Save
  • Theranostic trial of well differentiated neuroendocrine tumors (NETs) with 68Ga-OPS201 and 177Lu-OPS201
    Meeting Abstract

    Reidy-Lagunes, D.; Pandit-Taskar, N.; Krebs, S.; O'Donoghue, J.; Raj, N. P.; Cruz, E.; Pham, H.; Lashley, A.; Bodei, L.; Weber, W.
    Pancreas (2018)

    Fulltext@MSK | Save